Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Notes Payables (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Notes Payables data on record, last reported at $100000.0 in Q2 2025.

  • For Q2 2025, Notes Payables fell 93.56% year-over-year to $100000.0; the TTM value through Jun 2025 reached $100000.0, down 93.56%, while the annual FY2024 figure was $1.1 million, 987.87% up from the prior year.
  • Notes Payables reached $100000.0 in Q2 2025 per COEP's latest filing, roughly flat from $100000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $2.4 million in Q4 2021 and bottomed at $100000.0 in Q4 2023.
  • Average Notes Payables over 5 years is $1.2 million, with a median of $1.4 million recorded in 2023.
  • Peak YoY movement for Notes Payables: soared 1366.67% in 2023, then tumbled 95.43% in 2025.
  • A 5-year view of Notes Payables shows it stood at $2.4 million in 2021, then dropped by 23.46% to $1.8 million in 2022, then tumbled by 94.59% to $100000.0 in 2023, then skyrocketed by 987.87% to $1.1 million in 2024, then plummeted by 90.81% to $100000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $100000.0 in Q2 2025, $100000.0 in Q1 2025, and $1.1 million in Q4 2024.